FDA expands use of Qiagen lung cancer mutation test

By LabPulse.com staff writers

The U.S. Food and Drug Administration (FDA) approved the expanded use of a Qiagen diagnostic kit as a companion test for the identification of nonsmall cell lung cancer patients who may be eligible for treatment with a newly approved drug.

Qiagen's polymerase chain reaction (PCR) test, the Therascreen KRAS RGQ PCR kit, is a tissue-based test that identifies the KAS KRAS G12C mutation in nonsmall cell lung cancer; the FDA approved the test for expanded use with Amgen's sotorasib (Lumakras). KRAS is one of the most frequently occurring mutations in this type of cancer.

The kit, which will be via Qiagen's Day One Lab Readiness program, is used with the Rotor-Gene Q MDx instrument.

Copyright © 2021 LabPulse.com

To read this and get access to all of the exclusive content on LabPulse.com, create a free account or sign in now.

Member Sign In:
MemberID or email address:  
Do you have a LabPulse.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?